Hydromorphone
| Hydromorphone | |
|---|---|
| Salts [] | |
|---|---|
| Hydromorphone hydrochloride | |
| Hydromorphone sulfate | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 285.34 g/mol [1] |
| Appearance | Crystals from ethanol [1] |
| Odor | Odorless [1] |
| Melting point | Decomposes at 305ºC [1] |
| Boiling point | Decomposes at 305ºC [1] |
| Decomposition | When heated to decomposition it emits toxic fumes of /nitrogen oxides/. [1] |
| Solubility | Highly soluble [1] |
| Predicted LogP | 1.8 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C17H19NO3 |
| IUPAC name | (4R,4aR,7aR,12bS)-9-hydroxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one |
| SMILES | CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3C(=O)CC4 |
| InChI | InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1 |
| InChIKey | WVLOADHCBXTIJK-YNHQPCIGSA-N |
| CAS number | 466-99-9 |
| UNII | Q812464R06 |
| PubChem CID | 5284570 |
| Pharmacokinetics[] | |
|---|---|
| Onset | 15–30 min |
| Elimination half-life | 2–3 hours[3] |
| Duration of action | 4–5 hours |
| Metabolism | Liver |
| Excretion | Kidney |
| Routes of administration | By mouth, intramuscular, intravenous, subcutaneous |
| Dependence liability | High[4] |
| Addiction liability | High |
| Toxicity [] | |
|---|---|
| LD50 | Mouse: - sc: 84 mg/kg - iv: 104 mg/kg [1] |
| Dosing[] |
|---|
| Intravenous [] | |
|---|---|
| Threshold | 1 |
| Light | 1 - 1.375 |
| Common | 1.375 - 4 |
| Strong | 4 |
| Heavy | 4 - 6.4499999999999975 |
| Oral [] | |
|---|---|
| Threshold | 1 - 2 |
| Light | ≤ 2 |
| Common | 2 - 2.5 |
| Strong | 2.5 - 4 |
| Heavy | 4 - 8 |
Statistically derived dosages via DBI-IGS (archived by anodyne.wiki) We do not take any responsibility for medical complications or loss of life sustained by following these dosages blindly. |
Hydromorphone (also known as Dihydromorphinone, Dimorphone, Hydromorphon, Idromorfone, Novolaudon, Dihydromorfinon, Hidromorfona, Hydromorfona, Laudacon or 7,8-Dihydromorphinone) is a antidepressant, depressant, hormone and opioid substance of the 2-benzylpiperidine and morphinan class.
Chemistry
Salts []
Stereochemistry []
Hydromorphone is a single defined stereoisomer.
Druglikeness
Lipinski's rule of five
Hydromorphone matches Lipinski's rule of five.Reagents
There are currently 4 reagent-interactions on DrugsPRO
| Reagent | Color change | Description |
|---|---|---|
| Marquis | yellow > red / magenta | |
| Mecke | yellow > orange / brown | |
| Mandelin | no color change | |
| Froehde | blue > purple / grey |
Pharmacology
ATC Classification
- nervous system (N)
- analgesics (N02)
- opioids (N02A)
- natural opium alkaloids (N02AA)
- (N02AA03)
- hydromorphone (N02AA03)
MeSH Classification
Mechanism of action []
Hydromorphone is an opioid agonist that can bind to different types of opioid receptors. Its analgesic effect is suggested to be related to the effect on the mu-opioid receptors. It has been reported to also have a minor affinity for the delta and kappa receptor. On the other hand, it is known to act at the level of the medulla which allows it to depress the respiratory drive and suppress cough. The onset of action of the immediate release form of hydromorphone is achieved in 15-20 minutes and having a lasting effect for 3-4 hours while the extended-release form onset of action is of 6 hours lasting for about 13 hours. [1]
Interactions []
Medical side effects []
289 side effects listed on drug labels in SIDER 4.1 (hydromorphone).
- Constipation
- Nausea
- Asthenia
- Fatigue
- Somnolence
- Drowsiness
- Headache
- Vomiting
- Diarrhoea
- Insomnia
- Pruritus
- Back pain
- Low back pain
- Dizziness
- Syncope
- Lightheadedness
- Drug withdrawal syndrome
- Withdrawal symptom
- Dyspepsia
- Depression
- Dyspnoea
- Abdominal pain
- Gastrointestinal pain
- Anxiety
- Apprehension
- Arthralgia
- Musculoskeletal discomfort
- Myalgia
- Hyperhidrosis
- Sweating
- Sweating increased
- Dry mouth
- Oedema peripheral
- Dermatitis
- Rash
- Pain in extremity
- Pain
- Acute pain
- Ache
- Pain worsened
- Muscle spasms
- Cramps of lower extremities
- Cramp muscle
- Decreased appetite
- Appetite absent
- Body temperature increased
- Chest pain
- Chest discomfort
- Chest tightness
- Weight decreased
- Anaphylactic shock
- Anaphylactoid reaction
- Angioedema
- Confusional state
- Feeling abnormal
- Malaise
- Dyskinesia
- Hyperpathia
- Hyperaesthesia
- Hypersensitivity
- Immune system disorder
- Myoclonus
- Convulsion
- Urticaria
- Welts
- Injection site reaction
- Skin disorder
- Hepatic enzyme increased
- Erectile dysfunction
- Oropharyngeal swelling
- Abdominal distension
- Fullness abdominal
- Addison's disease
- Aggression
- Alcoholism
- Alcohol abuse
- Amnesia
- Apnoea
- Arrhythmia
- Asthma
- Barrett's oesophagus
- Mental disorder
- Breast disorder
- Breast feeding
- Bronchospasm
- Cheyne-Stokes respiration
- Cognitive disorder
- Coma
- Infection
- Connective tissue disorder
- Contusion
- Cough
- Cyanosis
- Libido decreased
- Disturbance in sexual arousal
- Dysphagia
- Dehydration
- Diplopia
- Diverticulitis
- Diverticulum
- Drug abuse
- Drug tolerance
- Duodenitis
- Dysarthria
- Osteoarthritis
- Arthropathy
- Dysgeusia
- Dysuria
- Ear pain
- Endocrine disorder
- Eructation
- Gastrooesophageal reflux disease
- Eye disorder
- Faecalith
- Faecaloma
- Anal fissure
- Flatulence
- Flushing
- Gastritis
- Gastroenteritis
- Gastrointestinal disorder
- Hallucination
- Head injury
- Cardiac arrest
- Cardiac disorder
- Haematochezia
- Haemorrhoids
- Hepatomegaly
- Hiccups
- Hypercalcaemia
- Hypertension
- Hyperventilation
- Hypoaesthesia
- Hypogonadism
- Hyponatraemia
- Hypotension
- Hypotensive
- Orthostatic hypotension
- Body temperature decreased
- Hypothermia
- Incontinence
- Intestinal obstruction
- Laryngospasm
- Lethargy
- Leukopenia
- Lung disorder
- Mediastinal disorder
- Menstrual disorder
- Miosis
- Hypotonia
- Muscle relaxant therapy
- Muscle rigidity
- Nervous system disorder
- Nervousness
- Feeling jittery
- Tension
- Nystagmus
- Oliguria
- Palpitations
- Ileus paralytic
- Paraesthesia
- Piloerection
- Cutis anserina
- Polyuria
- Urine output increased
- Post herpetic neuralgia
- Pulmonary oedema
- Rhinitis
- Chills
- Shock
- Sneezing
- Stomatitis
- Withdrawal syndrome
- Completed suicide
- Swelling
- Loss of consciousness
- Tachycardia
- Ventricular tachycardia
- Tinnitus
- Tremor
- Tremor muscle
- Erythema
- Azotaemia
- Urethral stenosis
- Pollakiuria
- Micturition disorder
- Urethral disorder
- Urinary tract disorder
- Angiopathy
- Vertigo
- Wheezing
- Yawning
- Urinary retention
- Encephalopathy
- Stupor
- Depressed level of consciousness
- Agitation
- Apathy
- Flat affect
- Mood swings
- Affect lability
- Panic attack
- Migraine
- Injury
- Large intestine perforation
- Intracranial pressure increased
- Accidental overdose
- Biliary colic
- Injection site pain
- Paranoia
- Hyporeflexia
- Hyperreflexia
- Aspartate aminotransferase increased
- Gastric atony
- Impaired gastric emptying
- Delayed gastric emptying
- Urinary hesitation
- Abnormal faeces
- Respiratory arrest
- Malnutrition
- Brain cancer metastatic
- Metastases to central nervous system
- Hangover
- Discomfort
- Ill-defined disorder
- Increased appetite
- Disorientation
- Disturbance in attention
- Dysphoria
- Memory impairment
- Abnormal dreams
- Respiratory depression
- Pulmonary function test decreased
- Muscle contractions involuntary
- Euphoric mood
- Sedation
- Cold sweat
- Dyschezia
- Early satiety
- Hepatobiliary disease
- Fluid retention
- Drug dependence
- Dependence
- Walking disability
- Gait disturbance
- Dry eye
- Induration
- Extrasystoles
- Vision blurred
- Abdominal pain upper
- Injection site urticaria
- Balance disorder
- Bradycardia
- Respiratory distress
- Coordination abnormal
- Application site pain
- Instillation site pain
- Feeling drunk
- Visual impairment
- Altered state of consciousness
- Feeling of body temperature change
- Sexual dysfunction
- Drug interaction
- Presyncope
- Blood uric acid increased
- Hyperuricaemia
- Substance abuse
- Bedridden
- Oxygen saturation decreased
- Infestation
- Amylase increased
- Blood testosterone decreased
- Blood potassium decreased
- Gastrointestinal motility disorder
- Muscular weakness
- Ureteral spasm
- Breakthrough pain
- Respiratory failure
- Ileus
- Nasopharyngitis
- Rhinorrhoea
- Respiratory disorder
- Respiration abnormal
- Tumour invasion
- Bezoar
- Psychotic disorder
- Cardiovascular insufficiency
- Therapy naive
- Feeling hot
Indications
- Acute pain
- Acute ulcerative colitis
- Advanced cancer
- Biliary colic
- Burn
- Cancer pain
- Chronic pain
- Colitis ulcerative
- Discomfort
- Myocardial infarction
- Neoplasm malignant
- Pain
- Postoperative pain
- Renal colic
- Trauma
Subjective effects []
Experience reports
Erowid
There are currently 30 experience reports involving hydromorphone on Erowid: []- "How Ironic" by Drew
- "Patch Overdose and Four Day Hell" by TMG
- "A Long Lonely Struggle" by White Stallion
- "What Can Go Wrong with Needles" by Taylor
- "A Hedonistic Dream" by Dondante
- "Sedate Euphoria" by med friend
- "36 Hours With My Lady D" by Vander
- "I Feel Like I Didn't Shower for a Week" by theAngryLittleBunny
- "Waves of Calm and Happy" by Halcyon
- "This Feels Weird" by pain in the rear
- "Intense Pain Calls For Intense Pain Relief" by Entropy
- "Bouyancy" by HeyNC
- "Trip to the ER" by SobeDog
- "X'ed Out without MDMA" by Jesus Raves
- "Perfect Pain Relief" by DrGT
- "Low-Key Yet Intense Exhilaration" by Darkbloom
- "Dullness and the Law of Diminishing Returns" by Seifuru
- "Warm Liquid Ooze" by MrShankly
- "The Pull of the Needle" by Matt
- "A More Refined Speedball" by Marz
- "The Bobbing Head" by Yurt
- "Dreamy Bliss of Nothing" by D Peyo
- "Into the Gentle Night" by William H.
- "Completely and Utterly Rushed" by Caffein Commando
- "Dancing with Dilaudid, the Devil in Dolophine" by Doc
- "Simple 'Nothingness'" by CM
- "A Respite From Pain and a Full Life!" by juneleaves
- "Small Orange Circles of Opiate Perfection" by HigherThanEver
- "One of a Handful of People" by Ree
- "Punching Through" by NCOTCL Darth Hoosier
Legal status []
- Australia: Hydromorphone is a Schedule 8.
- Brazil: Hydromorphone is a A1.[5]
- Canada: Hydromorphone is a Schedule I.
- Germany: Hydromorphone is a Anlage III under the "Betäubungsmittelgesetz (BtMG)".
- New Zealand: Hydromorphone is a Class B.
- United Kingdom: Hydromorphone is a Class A Controlled Drug: Schedule II under the "Misuse of Drugs Act 1971".
- United States: Hydromorphone is a Schedule II under the "Controlled Substances Act".
- United Nations: Hydromorphone is a Schedule I narcotic under the "Single Convention on Narcotic Drugs 1961".
- Other: Hydromorphone is a SE: Förteckning II.
See also []
External links []
- Hydromorphone (Wikipedia)
- Hydromorphone (PubChem)
- Hydromorphone (Wikidata)
- Hydromorphone (DrugBank)
- Hydromorphone (ChEMBL)
- Hydromorphone (ChEBI)
- Hydromorphone (Common Chemistry)
- Hydromorphone (HMDB)
- Hydromorphone (KEGG)
- Hydromorphone (EPA DSSTox)
- Hydromorphone (Effect Index)
- Hydromorphone (UNII)
- Hydromorphone (SIDER)
- Hydromorphone (Erowid)
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 5284570, Hydromorphone. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5284570
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Hydromorphone. UNII: Q812464R06. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/Q812464R06
Vallner JJ, Stewart JT, Kotzan JA, Kirsten EB, Honigberg IL. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. Journal of Clinical Pharmacology. April 1981; 21(4):152–156. PMID 6165742. https://doi.org/10.1002/j.1552-4604.1981.tb05693.x
Bonewit-West K, Hunt SA, Applegate E. Today's Medical Assistant: Clinical and Administrative Procedures. Elsevier Health Sciences. 2012. https://books.google.com/books?id=YalYPI1KqTQC&pg=PA571
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | ok | 2026-11-20 16:01:55 |
| drugspro | ok | 2026-11-20 16:01:51 |
| erowid | ok | 2026-11-20 16:01:53 |
| gsrs | ok | 2026-11-20 16:01:52 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014472) | 2026-11-20 16:01:51 |
| kegg | ok | 2026-11-20 16:01:54 |
| pubchem | ok | 2026-11-20 16:01:50 |
| ok | 2026-11-20 16:01:51 | |
| sider | ok | 2026-11-20 16:01:51 |
| structure | ok | 2026-11-20 16:01:51 |
| wikipedia | ok | 2026-11-20 16:01:51 |